Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $3.3352W HIGH $9.16
Volume
21.99 K
Value Traded
835.58 K
Short % Float
7.34%
+12.72%Week
-4.87%1 Month
-13.61%3 Month
-22.87%6 Month
-85.18%5 Year
-65.97%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
267.37 M
EPS (TTM)
-2.72
P/E Ratio
-
Ent. Value
-243.38 M
Total Shares
69.99 M
Float Shares
45.40 M
Insiders
9.89%
Institutions
64.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
BCYC Catalyst Timeline
Dated clinical, regulatory and corporate events for Bicycle Therapeutics plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bicycle Therapeutics plc
282Total events
14Upcoming
62Tier-1 (high impact)
2019 to 2030Coverage
Upcoming catalysts 2
Event history 50
▲Trial Initiationzelenectide pevedotinTrial
Duravelo-4 trial open and actively recruiting patients
NECTIN4-amplified non-small cell lung cancersource ↗
▼Trial Pausedzelenectide pevedotinTrial
Paused Phase 1/2 Duravelo-5 trial in multiple tumors
multiple tumorssource ↗
▼Restructuring LayoffsCorporate
Implemented workforce reduction and strategic cost realignment of ~30%
◆Oral Presentationzelenectide pevedotinPresentation
Interim analysis results from Duravelo-2: zelenectide pevedotin + pembrolizumab in previously untreated la/mUC
previously untreated locally advanced/metastatic urothelial carcinomasource ↗
▲Topline Readoutzelenectide pevedotinClinical Data
Initial Duravelo-2 data presented at ASCO 2026
metastatic urothelial cancer (mUC)source ↗
◆Poster Presentationzelenectide pevedotinPresentation
Zelenectide pevedotin plus pembrolizumab in 1L cisplatin-ineligible la/mUC: Update on Duravelo-1 B7
1L cisplatin-ineligible locally advanced/metastatic urothelial carcinomasource ↗
◆Oral Presentationzelenectide pevedotinPresentation
Initial dose selection data from Duravelo-2 to be presented at ASCO 2026
metastatic urothelial cancer (mUC)source ↗
◆Oral Presentationnuzefatide pevedotinPresentation
Update on Nuzefatide Pevedotin and EphA2 Pipeline at AACR 2026
▲First Patient Dosednuzefatide pevedotinTrial
First patient dosed in Phase 2 trial of nuzefatide in recurrent PDAC
recurrent pancreatic ductal adenocarcinoma (PDAC)source ↗
▼Trial Discontinuedzelenectide pevedotinTrial
Duravelo-4 trial to be discontinued
NECTIN4-amplified non-small cell lung cancersource ↗
▼Program Discontinuationzelenectide pevedotinCorporate
Zelenectide program deprioritized for internal development
mUCsource ↗
▲Partnership / LicenseCorporate
15-year contract with UK Nuclear Decommissioning Authority for RepU access
●Enrollment Updatenuzefatide pevedotinTrial
Enrollment started for Phase 2 trial of nuzefatide in PDAC
recurrent pancreatic ductal adenocarcinoma (PDAC)source ↗
▼Trial Discontinuedzelenectide pevedotinTrial
Discontinuation of Duravelo-4 trial for zelenectide in NSCLC
NECTIN4-amplified non-small cell lung cancersource ↗
▼Program Discontinuationzelenectide pevedotinCorporate
Deprioritization of zelenectide for internal development; converting Duravelo-2 to randomized Phase 2
mUCsource ↗
▲Trial Initiationnuzefatide pevedotinTrial
Phase 2 trial enrollment started for nuzefatide pevedotin in PDAC
recurrent pancreatic ductal adenocarcinomasource ↗
◆Dose Finding Updatezelenectide pevedotinTrial
Dose selection from Phase 2/3 Duravelo-2 trial expected
metastatic urothelial cancersource ↗
◆FDA Feedback Receivedzelenectide pevedotinFDA Meeting
Update on potential approval pathway expected in 1Q 2026
metastatic urothelial cancersource ↗
▲Oral Presentationnuzefatide pevedotinPresentation
Data presented at AACR Annual Meeting 2026
EphA2 expressing cancerssource ↗
◆Timing Guidancezelenectide pevedotinPresentation
Update on dose selection for Phase 2/3 Duravelo-2 pivotal trial and potential approval pathway in mUC following meetings with multiple regulatory agencies
metastatic urothelial cancersource ↗
▲Oral PresentationPresentation
EphA2 BIA human imaging data presented at AACR 2026
pancreatic ductal adenocarcinoma (PDAC)source ↗
●Oral PresentationPresentation
Participation in upcoming investor conference in November 2025
●Poster PresentationPresentation
E-poster presentation of early BRC molecule targeting MT1-MMP at EANM 2025
cancersource ↗
◆First Patient Dosedzelenectide pevedotinTrial
FDA meeting planned for 4Q 2025 to discuss dose selection and accelerated approval pathway
metastatic urothelial cancersource ↗
◆Timing Guidancezelenectide pevedotinPresentation
On track to provide update on dose selection from Duravelo-2 and accelerated approval pathway following FDA meeting in 4Q 2025
metastatic urothelial cancersource ↗
●Oral PresentationPresentation
Morgan Stanley Global Healthcare Conference fireside chat on Sept 9
◆Oral PresentationPresentation
Participation in upcoming investor conferences in September 2025
▲Trial Initiationzelenectide pevedotinTrial
Phase 1/2 Duravelo-4 trial for zelenectide pevedotin open and actively recruiting patients
NECTIN4-amplified non-small cell lung cancersource ↗
▼Restructuring LayoffsCorporate
Strategic cost realignment with workforce reduction of approximately 30%
▲Full Resultszelenectide pevedotinClinical Data
Updated Duravelo-1 data as of August 1, 2025 cutoff
metastatic urothelial cancersource ↗
▲Interim Analysiszelenectide pevedotinTrial
Interim analysis for Cohort 1 data cut on July 23, 2025
metastatic urothelial cancersource ↗
◆Timing Guidancezelenectide pevedotinPresentation
Dose selection in Phase 2/3 Duravelo-2 trial for metastatic urothelial cancer expected in second half of 2025
metastatic urothelial cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How BCYC actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | nuzefatide pevedotin (BT5528) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$398M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.4x
rNPV / MCap
Top 29%
Micro Cap(rank 192 of 658)
Percentile Rank
Bicycle Therapeutics plc carries a moderate pipeline score (45/100), with $1.6B risk-adjusted pipeline value, led by Zelenectide pevedotin in Non-Small Cell Lung Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Zelenectide pevedotin ADCNCT06225596 | Metastatic Urothelial Cancer | Phase 2 | ACTIVE NOT_RECRUITING | 375 | Mar 1, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every BCYC program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Bicycle Radioconjugates | various solid tumors | 2025-04-29 | 12 patients; SUVmax 6.0 g/mL vs. 10.3 g/mL; SUVmax 4.7 g/mL vs. 4.4 g/mL; SUVmax 7.9 g/mL vs. 6.0 g/mLRead More | Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025 Data continue to validate the potential of Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Thompson Travis AlvinOfficer (Chief Financial Officer) | Sell | -79 64,449 held | $3.57 | 10/05/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BCYC
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 0.2 % (-33.3 %) | 46.15 M | 10.89 M |
BCYC Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BCYC ranks across every disease it competes in
Competitive Position is a premium feature
See how BCYC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBCYC News
BCYCBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Bicycle Therapeutics plc has reported its financial results for the second quarter of 2026, highlighting significant progress in its business operations. The company is concentrating on its proprietary bicyclic peptide technology and the development of nuzefatide pevedotin. The management expressed satisfaction with the advancements made during this period.
Read more →BCYCBicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
Bicycle Therapeutics is set to present initial data from its Duravelo-2 study at the 2026 ASCO Annual Meeting. This presentation is anticipated to provide insights into the efficacy and safety of their therapeutic approach. Details regarding the specific findings or implications of the data have not yet been disclosed.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
Bicycle Therapeutics reported its first quarter 2026 financial results, highlighting positive developments in its drug candidates, particularly nuzefatide pevedotin. The company has initiated a Phase 2 trial for nuzefatide in pancreatic cancer and plans to present data at the upcoming ASCO Annual Meeting. Despite a decrease in collaboration revenue and a net loss, Bicycle is focusing on its promising pipeline and maintaining a robust cash position.
Read more →BCYC▼ -6.8%on this news
Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting
Bicycle Therapeutics announced its participation in the 2026 ASCO Annual Meeting, featuring an oral presentation and several poster presentations. The focus is on interim analysis results from studies involving their drug, zelenectide pevedotin, for treating locally advanced and metastatic urothelial carcinoma. The presentations will cover various aspects of the drug's efficacy and dosage optimization.
Read more →BCYCBicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026
Bicycle Therapeutics provided an update on its Nuzefatide Pevedotin and EphA2 pipeline during the AACR Annual Meeting 2026. The details of the update were not disclosed in the article. Further information may be available from the event.
Read more →BCYC▼ -7.3%on this news
Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026
Bicycle Therapeutics announced its participation in the AACR Annual Meeting 2026, featuring an oral presentation and multiple poster presentations. The company will present five abstracts, including studies on its BT5528 drug in various cancer models. This event highlights Bicycle's commitment to advancing cancer therapeutics through its innovative Bicycle technology.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
Bicycle Therapeutics reported its financial results for Q4 and full year 2025, highlighting the completion of dose selection for the Duravelo-2 trial and the decision to deprioritize the zelenectide program. The company plans to convert the ongoing trial to a randomized Phase 2 study and has initiated a strategic reprioritization of its pipeline, including workforce reductions. Additionally, Bicycle established partnerships to support its radiopharmaceutical pipeline.
Read more →BCYCBicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline
Bicycle Therapeutics has announced key leadership transitions, appointing Travis Thompson as CFO, Michael Method as CMO, and Michael Skynner as CSO. These changes are aimed at advancing the company's oncology pipeline and enhancing its operational capacity. The CEO expressed optimism about the company's financial position and upcoming strategic partnerships in oncology.
Read more →BCYCBicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026
Bicycle Therapeutics has outlined its key accomplishments from 2025 and set strategic priorities for 2026, focusing on the Phase 2/3 Duravelo-2 trial. The company is seeking feedback from regulatory agencies regarding the potential approval pathway for its therapies. Additionally, Bicycle is advancing its radiopharmaceutical pipeline, with new imaging data and updates from ongoing clinical trials expected in the coming year. The financial outlook remains positive, with sufficient runway projected to support these initiatives.
Read more →BCYCBicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline
Bicycle Therapeutics has established several strategic partnerships to develop its radiopharmaceutical pipeline. A 15-year contract with the UK Nuclear Decommissioning Authority will provide access to reprocessed uranium, essential for producing the therapeutic isotope 212 Pb. Collaborations with the UK National Nuclear Laboratory and SpectronRx aim to enhance the extraction and development of a bespoke 212 Pb generator, supporting the company's innovative cancer treatments.
Read more →BCYC▲ +7.1%on this news
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results
Bicycle Therapeutics has reported its financial results for Q3 2025, highlighting progress in the clinical development of its innovative drug candidates. The company is seeking regulatory feedback for its drug zelenectide pevedotin in metastatic urothelial cancer while continuing trials for various Nectin-4 associated cancers. Despite a reported net loss of $59.1 million, Bicycle maintains a strong cash position of $648.3 million, ensuring it has a financial runway until 2028. Notable enhancements to its leadership team were also disclosed to bolster innovation and strategic growth.
Read more →BCYCBicycle Therapeutics Strengthens Board of Directors with New Appointments
Bicycle Therapeutics has appointed Roger Dansey, M.D., and Herv Hoppenot to its Board of Directors, strengthening its leadership in oncology development. Dansey and Hoppenot bring significant experience from their previous roles at Pfizer, Seagen, Incyte, and Novartis. Bicycle is actively advancing its pipeline and anticipates several milestones in the near future. The company focuses on developing innovative therapies based on its proprietary Bicycle technology.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
Bicycle Therapeutics has reported its second quarter 2025 financial results, highlighting advancements in its clinical pipeline, particularly with the Phase 1/2 trial for zelenectide pevedotin. The company has strengthened its clinical leadership through new appointments and redefined its strategic direction amid a challenging macroeconomic environment. To optimize operations and extend their financial runway into 2028, Bicycle has announced a workforce reduction, which reflects a proactive approach towards ensuring operational flexibility and prioritizing high-impact programs. Despite recent operational losses, the company retains a solid cash position.
Read more →BCYC▲ +6.1%on this news
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
Bicycle Therapeutics has reported progress in business and financial results for Q1 2025. The company announced multiple abstract acceptances for presentation at the ASCO and AACR annual meetings, highlighting the potential of its oncology pipeline. Additionally, they initiated a Phase 1/2 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer and noted a solid cash position extending their runway into the second half of 2027. Growth in leadership and advisory boards was also mentioned as part of their strategy moving forward.
Read more →BCYCBicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
Bicycle Therapeutics has announced the presentation of additional human imaging data for MT1-MMP at the AACR Annual Meeting 2025, highlighting its potential as a novel cancer target. The data encompass findings from 12 patients with various solid tumors, demonstrating the applicability of Bicycle Radioconjugates (BRC) for radiopharmaceutical imaging. The company plans to initiate clinical trials for its BRCs in 2026 and anticipates initial human imaging data for its second target, EphA2, later this year. The results validate earlier preclinical data and position Bicycle's technology favorably for future cancer therapies.
Read more →BCYC▲ +5.3%on this news
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments
Bicycle Therapeutics has announced significant leadership changes, including Felix J. Baker, Ph.D., as the new chairman of the Board of Directors and the addition of oncology experts Alessandro Riva, M.D., to the Board and Fabrice Andr, M.D., to the Clinical Advisory Board. Eric Westin, M.D., has been promoted to chief medical officer, while Jim MacDonald-Clink has been elevated to senior vice president, head of business development. These appointments follow the planned retirement of several board members and are seen as a step towards strengthening the company's position in oncology drug development.
Read more →BCYCBicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full
Bicycle Therapeutics recently announced its fourth quarter and annual results for 2024, highlighting progress in its pipeline, particularly with zelenectide pevedotin showing promising anti-tumor activity in first-line metastatic urothelial cancer. The company received Fast Track designations from the FDA for treating advanced triple-negative breast cancer and non-small cell lung cancer, further showcasing its potential. Bicycle Therapeutics also plans to initiate multiple Phase 1/2 trials in the coming year and reported a strong cash position expected to facilitate operations into the second half of 2027. Additionally, the company is advancing its radiopharmaceutical development ahead of upcoming trials in 2026.
Read more →BCYC▲ +13.9%on this news
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
Bicycle Therapeutics announced updated topline results from a Phase 1 trial of its combination therapy, zelenectide pevedotin and pembrolizumab, for treating metastatic urothelial cancer. The data indicates promising anti-tumor activity and a favorable safety profile, reinforcing the therapy's potential as a leading treatment option. The company also outlined its strategic priorities for 2025, including advancements in its emerging pipeline and financial stability through 2027. Bicycle aims to revolutionize treatment for Nectin-4 associated cancers through ongoing trials and new indications.
Read more →BCYCBicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification Topline combination data for zelenectide pevedotin plus pembrolizumab in fir
Bicycle Therapeutics has announced positive data updates for its groenectide pevedotin program, particularly showcasing a 60% overall response rate in first-line metastatic urothelial cancer in combination with pembrolizumab. The company plans to advance its development strategy by leveraging NECTIN4 gene amplification, targeting breast cancer, lung cancer, and other tumors in 2025. Notable monotherapy responses were observed in heavily pretreated breast cancer patients, highlighting the potential of zelenectide pevedotin as a new treatment option. Despite ongoing enrollment in the Duravelo-2 trial, the differentiating safety profile and the promising efficacy data position Bicycle Therapeutics favorably in targeted cancer therapies.
Read more →About Bicycle Therapeutics plc
HeadquartersBLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, X0, CB21 6GS
Founded2009
BIOPHARMAWATCH ELITE PLUS
Trade the next BCYC catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime